Get started
NOVO has developed an H&S formationAs others have also mentioned on Trading View, NOVO has developed an H&S formation. The formation is to some extent supported by volume. Volume should be large when forming the left shoulder 1, as well as when forming the head 2, and when the price goes down at the right shoulder 4, but when forming the right shoulder the volume should be low 3. It is not. Since May, the volume balance has been negative, i.e. high volume at the price bottom and low volume at the price peak. At 794, there will be a significant break of 3%, especially if it is supported by high volume. There is no significant break yet. The object is heading towards 629. An H&S formation is a reversal formation. NOVO has been in a bullish trend, according to MA. However, the price is now below SMA 200. The price momentum indicators go from sell to buy within a month on Trading View. The price is well below a red cloud in Ichimocu. It is not possible to say now whether we will have a significant break down or whether the price will recover. The forecast will depend on this. Fundamentally, analysts are predominantly positive about the stock. Many companies would like to enter the obesity market, but there are far from good results in a phase 1 study to a finished drug, if it becomes a drug at all. Disclaimer: I have a relatively large position in the stock, which I bought when the shares plunged during the covid19 epidemic. I have sold 1/4 share when the price had tripled, so I am thinking of sitting still now even in the face of the technical picture - I am long. In the past, price has fluctuated between two pivot lines at times. Then I have swing traded NOVO. NB: Remember you must do your own research and assessment before buying and selling.
OMXCOP:NOVO_B
by scorpiris
1
Novo Nordisk hit my target this week and I have started to buy The head and shoulders pattern successfully played out, with OMXCOP:NOVO_B reaching my full target at 670. Check out my original post: The stock experienced a significant drop, falling as much as 27% on the Friday before Christmas. This was triggered by test results for their obesity drug, CagriSema, which showed patient weight loss of 22.7% - below the anticipated 25%. I believe this reaction is an overcorrection and have taken advantage of this rare opportunity to purchase OMXCOP:NOVO_B , first at 680 and again at 600. I now plan to hold patiently, expecting Novo Nordisk to reach new all-time highs in the coming years.
OMXCOP:NOVO_BLong
by madsroland
Novo completely oversold🐂 Trade Idea: Long - NOVO 🔥 Account Risk: 20.00% 📈 Recommended Product: Stock 🔍 Entry: +/- 750.00 🐿 DCA: No 😫 Stop-Loss: 675.00 🎯 Take-Profit #1: 1,000.00 (50%) 🎯 Trail Rest: Yes 🚨🚨🚨 Important: Don’t forget to always wait for strong confirmation once possible entry zone is reached. Trade ideas don’t work all the time no matter how good they look. Do not get a victim of FOMO, there is always another trade idea waiting. 🚨🚨🚨 If you like what you see don’t forget to leave a comment 💬 or smash that like ❤️ button! — Novo Nordisk is completely oversold (in fear of RFK) and so is the rest of the Pharma sector as well. Nevertheless, Novo is still printing money and trial results for a new product should come in end 24 or beginning 25 for the oral version of the weight loss drug. The fear over political decisions in the US should be used to buy the Pharma sector. For me, it is Novo and Regeneron. — Disclaimer & Disclosures pursuant to §34b WpHG The trades shown here related to stocks, cryptos, commodities, ETFs and funds are always subject to risks. All texts as well as the notes and information do not constitute investment advice or recommendations. They have been taken from publicly available sources to the best of our knowledge and belief. All information provided (all thoughts, forecasts, comments, hints, advice, stop loss, take profit, etc.) are for educational and private entertainment purposes only. Nevertheless, no liability can be assumed for the correctness in each individual case. Should visitors to this site adopt the content provided as their own or follow any advice given, they act on their own responsibility.
OMXCOP:NOVO_BLong
by LGNDRY-Capital
2
MAERSK UptrendTREND According to the wave structure, it is still in the downtrend However, head and shoulders formation is a powerful reversal indicator. It also formed a blue channel , now targeting the upper band Moving Averages 20-day (Red) crosses 50-day (Orange) from down to up (powerful indicator supporting uptrend) 100-day (Turquoise) is below the current price (so supports uptrend) 200-day (Blue) is right below the current price (it becomes support now) SUMMARY Based on this analysis, a price action following the blue arrow is highly probable.
OMXCOP:MAERSK_BLong
by EmreSrn
NOVO Down TrendTREND The red trend line from 2022 has been broken. It may be doing a pullback for confirmation. It continues its movement within the orange channel that started in 2024. It may be the 3rd of the 5-wave. The green trend line from 2021 is the first target before the purple main support. The purple support formed in 2023 is the strongest level. It is also Fibo 0.618. MA 20-day (Red), 50-day (Orange) is cutting down from the top. 100-day (Turquoise) has been working as support since November. 200-day (Blue) intersects with the weekly main support (Purple). SUMMARY It is in a downtrend in the weekly and a typical reversal pattern is not seen. It may continue its movement in the direction of the blue arrow.
OMXCOP:NOVO_BShort
by EmreSrn
1
New Zealand dollar eyes RBNZ rate announcementThe New Zealand dollar is in positive territory on Tuesday, after a four-day losing streak. In the European session, NZD/USD is trading at 0.5850, up 0.09% on the day. Earlier, the New Zealand dollar fell as low as 0.5797, its lowest level since Nov. 1. The Reserve Bank of New Zealand makes its rate announcement on Wednesday and the markets have priced in a jumbo rate cut of a 50 basis point for a second straight meeting. This would bring the cash rate to 4.25%, its lowest level since November 2022. The RBNZ has done a good job of lowering inflation, which fell to 2.2% in the second quarter. This is the first time in over three years that inflation is within the target band of between 1 and 3 percent. Still, elevated rates have taken a heavy toll on the economy, as GDP declined 0.2% in the second quarter and likely fell in Q3 as well, which would mark a recession. The central bank’s aggressive rate-cutting is aimed at providing the economy with a much-needed boost. The New Zealand dollar stands to be the big loser from an oversized rate cut. The currency plunged around 1% after the 50-bp chop in October and we could see another sharp drop on Wednesday if the central bank cuts again by 50 basis points. The Federal Reserve releases the minutes of the November meeting later today. At the meeting, the Fed lowered rates by 25 basis points. Investors will be looking for insights about what the Fed may have planned for the Dec. 18 meeting. A few weeks ago, a second straight 25-bp cut appeared likely but with the US economy remaining strong, the Fed may opt to pause. Interest-rate future markets are currently pricing in a cut at 59% and a pause at 41%, according to the CME’s Fed Watch. NZD/USD is testing resistance at 0.5857. Above, there is resistance at 0.5898 There is support at 0.5793 and 0.5752
OMXCOP:FED
by OANDA
Revising the head and shoulders pattern on NOVOSince my previous analysis on Novo Nordisk OMXCOP:NOVO_B , the price has nearly reached the original target of 700. However, I have made slight adjustments to the head and shoulders pattern, which has consequently led to a revised target at the value area low of the range from late 2023 at around 670. At this point, I would not consider this an ideal time to initiate a short position on OMXCOP:NOVO_B . Instead, it appears to be more of a profit-taking opportunity for those who entered short positions near the levels indicated in my earlier post.
OMXCOP:NOVO_BShort
by madsroland
You can buy it here.. Its fineOMXCOP:VWS Recent pullback is a fine buying opportunity. Maybe we bottomed and break the downtrend now, Maybe we have a leg lower to ~120 - a chance to back up the truck. In any case this one will AT LEAST double in value over the next 3 years. Europe will make a lot of windmills in the next 3 years, it is vital for the future of European energy independence, so if you believe there is a future - then this is a good company to build a position in this winter. Cheers.
OMXCOP:VWSLong
by PotatoJuice99
4